Trials / Completed
CompletedNCT02443428
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this prospective observational registry is to monitor safety of eribulin in routine clinical practice. Additionally, this study will also assess the effectiveness of eribulin in real-life settings.
Conditions
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2015-05-13
- Last updated
- 2016-04-15
Locations
12 sites across 3 countries: Denmark, Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT02443428. Inclusion in this directory is not an endorsement.